Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target
Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 catalyzes the addition of methyl groups to histone H3 at lysine 9. Here, we describe how overexpression of SETDB1 contributes to melanoma tumorigenesis. SETDB1...
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 2019-12, Vol.145 (12), p.3462-3477 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3477 |
|---|---|
| container_issue | 12 |
| container_start_page | 3462 |
| container_title | International journal of cancer |
| container_volume | 145 |
| creator | Orouji, Elias Federico, Aniello Larribère, Lionel Novak, Daniel Lipka, Daniel B. Assenov, Yassen Sachindra, Sachindra Hüser, Laura Granados, Karol Gebhardt, Christoffer Plass, Christoph Umansky, Viktor Utikal, Jochen |
| description | Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 catalyzes the addition of methyl groups to histone H3 at lysine 9. Here, we describe how overexpression of SETDB1 contributes to melanoma tumorigenesis. SETDB1 is highly amplified in melanoma cells and in the patient tumors. Increased expression of SETDB1, which correlates with SETDB1 amplification, is associated with a more aggressive phenotype in in vitro and in vivo studies. Mechanistically, SETDB1 implements its effects via regulation of thrombospondin 1, and the SET‐domain of SETDB1 is essential for the maintenance of its tumorigenic activity. Inhibition of SETDB1 reduces cell growth in melanomas resistant to targeted treatments. Our results indicate that SETDB1 is a major driver of melanoma development and may serve as a potential future target for the treatment of this disease.
What's new?
Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 is known to be involved in malignant melanoma. However, little is known about its effects or mechanisms of action in humans. In this study, the authors found that increased SETDB1 expression is linked to poor prognosis in melanoma patients, and that SETDB1 regulates expression of the oncogene THBS1. They also found that inhibiting SETDB1 leads to a strong reduction in melanoma‐cell viability. This enzyme may thus offer a novel therapeutic target. |
| doi_str_mv | 10.1002/ijc.32432 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2232115728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2307156497</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3882-185845c3178f644273a2b56f0dbbe52fc66ad4f748915b92900e87f0040b3f4c3</originalsourceid><addsrcrecordid>eNp10U9LHDEYBvAgLXW1PfgFJNBLexjNv5lkjnar1SL0oD2HTPaNZplJ1iTTZb99U1d7KBQC7yE_HpL3QeiEkjNKCDv3a3vGmeDsAC0o6WVDGG3foEW9I42kvDtERzmvCaG0JeIdOuSUcqqkWqDttc8lBsATlMfdWJIJ2UEyGfDd5f3XLxTbGEryw1wg4xKrG02Ik8FlnmLyDxAg-4xNWOEM6VdFph4cYIs3sUAo3oy4PNbIDczFW1xMeoDyHr11Zszw4WUeo59Xl_fL6-b2x7eb5cVtY7lSrKGqVaK1nErlOiGY5IYNbefIahigZc52nVkJJ4XqaTv0rCcElHSECDJwJyw_Rp_2uZsUn2bIRU8-WxjrJyDOWTPGWd2KZKrSj__QdZxTqK_TjBNJ2070sqrPe2VTzDmB05vkJ5N2mhL9pw1d29DPbVR7-pI4DxOs_srX9VdwvgdbP8Lu_0n65vtyH_kb1lWTwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2307156497</pqid></control><display><type>article</type><title>Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Orouji, Elias ; Federico, Aniello ; Larribère, Lionel ; Novak, Daniel ; Lipka, Daniel B. ; Assenov, Yassen ; Sachindra, Sachindra ; Hüser, Laura ; Granados, Karol ; Gebhardt, Christoffer ; Plass, Christoph ; Umansky, Viktor ; Utikal, Jochen</creator><creatorcontrib>Orouji, Elias ; Federico, Aniello ; Larribère, Lionel ; Novak, Daniel ; Lipka, Daniel B. ; Assenov, Yassen ; Sachindra, Sachindra ; Hüser, Laura ; Granados, Karol ; Gebhardt, Christoffer ; Plass, Christoph ; Umansky, Viktor ; Utikal, Jochen</creatorcontrib><description>Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 catalyzes the addition of methyl groups to histone H3 at lysine 9. Here, we describe how overexpression of SETDB1 contributes to melanoma tumorigenesis. SETDB1 is highly amplified in melanoma cells and in the patient tumors. Increased expression of SETDB1, which correlates with SETDB1 amplification, is associated with a more aggressive phenotype in in vitro and in vivo studies. Mechanistically, SETDB1 implements its effects via regulation of thrombospondin 1, and the SET‐domain of SETDB1 is essential for the maintenance of its tumorigenic activity. Inhibition of SETDB1 reduces cell growth in melanomas resistant to targeted treatments. Our results indicate that SETDB1 is a major driver of melanoma development and may serve as a potential future target for the treatment of this disease.
What's new?
Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 is known to be involved in malignant melanoma. However, little is known about its effects or mechanisms of action in humans. In this study, the authors found that increased SETDB1 expression is linked to poor prognosis in melanoma patients, and that SETDB1 regulates expression of the oncogene THBS1. They also found that inhibiting SETDB1 leads to a strong reduction in melanoma‐cell viability. This enzyme may thus offer a novel therapeutic target.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.32432</identifier><identifier>PMID: 31131878</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Animals ; Cancer ; Carcinogenesis - genetics ; Carcinogenesis - pathology ; Epigenesis, Genetic - genetics ; epigenetic regulation ; gene amplification ; Gene Expression Regulation, Neoplastic - genetics ; Histone H3 ; Histone methyltransferase ; Histone-Lysine N-Methyltransferase - genetics ; Histones ; Histones - genetics ; Humans ; Lysine ; Lysine - genetics ; Maintenance ; Medical research ; Medical treatment ; Melanoma ; Melanoma - genetics ; Melanoma - pathology ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Phenotypes ; prognosis ; SETDB1 ; Therapeutic applications ; therapy ; Thrombospondin ; tumor progression ; Tumorigenesis ; Tumors</subject><ispartof>International journal of cancer, 2019-12, Vol.145 (12), p.3462-3477</ispartof><rights>2019 UICC</rights><rights>2019 UICC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3882-185845c3178f644273a2b56f0dbbe52fc66ad4f748915b92900e87f0040b3f4c3</citedby><cites>FETCH-LOGICAL-c3882-185845c3178f644273a2b56f0dbbe52fc66ad4f748915b92900e87f0040b3f4c3</cites><orcidid>0000-0002-7413-1383 ; 0000-0001-5316-0241</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.32432$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.32432$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31131878$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orouji, Elias</creatorcontrib><creatorcontrib>Federico, Aniello</creatorcontrib><creatorcontrib>Larribère, Lionel</creatorcontrib><creatorcontrib>Novak, Daniel</creatorcontrib><creatorcontrib>Lipka, Daniel B.</creatorcontrib><creatorcontrib>Assenov, Yassen</creatorcontrib><creatorcontrib>Sachindra, Sachindra</creatorcontrib><creatorcontrib>Hüser, Laura</creatorcontrib><creatorcontrib>Granados, Karol</creatorcontrib><creatorcontrib>Gebhardt, Christoffer</creatorcontrib><creatorcontrib>Plass, Christoph</creatorcontrib><creatorcontrib>Umansky, Viktor</creatorcontrib><creatorcontrib>Utikal, Jochen</creatorcontrib><title>Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 catalyzes the addition of methyl groups to histone H3 at lysine 9. Here, we describe how overexpression of SETDB1 contributes to melanoma tumorigenesis. SETDB1 is highly amplified in melanoma cells and in the patient tumors. Increased expression of SETDB1, which correlates with SETDB1 amplification, is associated with a more aggressive phenotype in in vitro and in vivo studies. Mechanistically, SETDB1 implements its effects via regulation of thrombospondin 1, and the SET‐domain of SETDB1 is essential for the maintenance of its tumorigenic activity. Inhibition of SETDB1 reduces cell growth in melanomas resistant to targeted treatments. Our results indicate that SETDB1 is a major driver of melanoma development and may serve as a potential future target for the treatment of this disease.
What's new?
Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 is known to be involved in malignant melanoma. However, little is known about its effects or mechanisms of action in humans. In this study, the authors found that increased SETDB1 expression is linked to poor prognosis in melanoma patients, and that SETDB1 regulates expression of the oncogene THBS1. They also found that inhibiting SETDB1 leads to a strong reduction in melanoma‐cell viability. This enzyme may thus offer a novel therapeutic target.</description><subject>Animals</subject><subject>Cancer</subject><subject>Carcinogenesis - genetics</subject><subject>Carcinogenesis - pathology</subject><subject>Epigenesis, Genetic - genetics</subject><subject>epigenetic regulation</subject><subject>gene amplification</subject><subject>Gene Expression Regulation, Neoplastic - genetics</subject><subject>Histone H3</subject><subject>Histone methyltransferase</subject><subject>Histone-Lysine N-Methyltransferase - genetics</subject><subject>Histones</subject><subject>Histones - genetics</subject><subject>Humans</subject><subject>Lysine</subject><subject>Lysine - genetics</subject><subject>Maintenance</subject><subject>Medical research</subject><subject>Medical treatment</subject><subject>Melanoma</subject><subject>Melanoma - genetics</subject><subject>Melanoma - pathology</subject><subject>Mice</subject><subject>Mice, Inbred NOD</subject><subject>Mice, SCID</subject><subject>Phenotypes</subject><subject>prognosis</subject><subject>SETDB1</subject><subject>Therapeutic applications</subject><subject>therapy</subject><subject>Thrombospondin</subject><subject>tumor progression</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10U9LHDEYBvAgLXW1PfgFJNBLexjNv5lkjnar1SL0oD2HTPaNZplJ1iTTZb99U1d7KBQC7yE_HpL3QeiEkjNKCDv3a3vGmeDsAC0o6WVDGG3foEW9I42kvDtERzmvCaG0JeIdOuSUcqqkWqDttc8lBsATlMfdWJIJ2UEyGfDd5f3XLxTbGEryw1wg4xKrG02Ik8FlnmLyDxAg-4xNWOEM6VdFph4cYIs3sUAo3oy4PNbIDczFW1xMeoDyHr11Zszw4WUeo59Xl_fL6-b2x7eb5cVtY7lSrKGqVaK1nErlOiGY5IYNbefIahigZc52nVkJJ4XqaTv0rCcElHSECDJwJyw_Rp_2uZsUn2bIRU8-WxjrJyDOWTPGWd2KZKrSj__QdZxTqK_TjBNJ2070sqrPe2VTzDmB05vkJ5N2mhL9pw1d29DPbVR7-pI4DxOs_srX9VdwvgdbP8Lu_0n65vtyH_kb1lWTwA</recordid><startdate>20191215</startdate><enddate>20191215</enddate><creator>Orouji, Elias</creator><creator>Federico, Aniello</creator><creator>Larribère, Lionel</creator><creator>Novak, Daniel</creator><creator>Lipka, Daniel B.</creator><creator>Assenov, Yassen</creator><creator>Sachindra, Sachindra</creator><creator>Hüser, Laura</creator><creator>Granados, Karol</creator><creator>Gebhardt, Christoffer</creator><creator>Plass, Christoph</creator><creator>Umansky, Viktor</creator><creator>Utikal, Jochen</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7413-1383</orcidid><orcidid>https://orcid.org/0000-0001-5316-0241</orcidid></search><sort><creationdate>20191215</creationdate><title>Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target</title><author>Orouji, Elias ; Federico, Aniello ; Larribère, Lionel ; Novak, Daniel ; Lipka, Daniel B. ; Assenov, Yassen ; Sachindra, Sachindra ; Hüser, Laura ; Granados, Karol ; Gebhardt, Christoffer ; Plass, Christoph ; Umansky, Viktor ; Utikal, Jochen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3882-185845c3178f644273a2b56f0dbbe52fc66ad4f748915b92900e87f0040b3f4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Cancer</topic><topic>Carcinogenesis - genetics</topic><topic>Carcinogenesis - pathology</topic><topic>Epigenesis, Genetic - genetics</topic><topic>epigenetic regulation</topic><topic>gene amplification</topic><topic>Gene Expression Regulation, Neoplastic - genetics</topic><topic>Histone H3</topic><topic>Histone methyltransferase</topic><topic>Histone-Lysine N-Methyltransferase - genetics</topic><topic>Histones</topic><topic>Histones - genetics</topic><topic>Humans</topic><topic>Lysine</topic><topic>Lysine - genetics</topic><topic>Maintenance</topic><topic>Medical research</topic><topic>Medical treatment</topic><topic>Melanoma</topic><topic>Melanoma - genetics</topic><topic>Melanoma - pathology</topic><topic>Mice</topic><topic>Mice, Inbred NOD</topic><topic>Mice, SCID</topic><topic>Phenotypes</topic><topic>prognosis</topic><topic>SETDB1</topic><topic>Therapeutic applications</topic><topic>therapy</topic><topic>Thrombospondin</topic><topic>tumor progression</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orouji, Elias</creatorcontrib><creatorcontrib>Federico, Aniello</creatorcontrib><creatorcontrib>Larribère, Lionel</creatorcontrib><creatorcontrib>Novak, Daniel</creatorcontrib><creatorcontrib>Lipka, Daniel B.</creatorcontrib><creatorcontrib>Assenov, Yassen</creatorcontrib><creatorcontrib>Sachindra, Sachindra</creatorcontrib><creatorcontrib>Hüser, Laura</creatorcontrib><creatorcontrib>Granados, Karol</creatorcontrib><creatorcontrib>Gebhardt, Christoffer</creatorcontrib><creatorcontrib>Plass, Christoph</creatorcontrib><creatorcontrib>Umansky, Viktor</creatorcontrib><creatorcontrib>Utikal, Jochen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orouji, Elias</au><au>Federico, Aniello</au><au>Larribère, Lionel</au><au>Novak, Daniel</au><au>Lipka, Daniel B.</au><au>Assenov, Yassen</au><au>Sachindra, Sachindra</au><au>Hüser, Laura</au><au>Granados, Karol</au><au>Gebhardt, Christoffer</au><au>Plass, Christoph</au><au>Umansky, Viktor</au><au>Utikal, Jochen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2019-12-15</date><risdate>2019</risdate><volume>145</volume><issue>12</issue><spage>3462</spage><epage>3477</epage><pages>3462-3477</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 catalyzes the addition of methyl groups to histone H3 at lysine 9. Here, we describe how overexpression of SETDB1 contributes to melanoma tumorigenesis. SETDB1 is highly amplified in melanoma cells and in the patient tumors. Increased expression of SETDB1, which correlates with SETDB1 amplification, is associated with a more aggressive phenotype in in vitro and in vivo studies. Mechanistically, SETDB1 implements its effects via regulation of thrombospondin 1, and the SET‐domain of SETDB1 is essential for the maintenance of its tumorigenic activity. Inhibition of SETDB1 reduces cell growth in melanomas resistant to targeted treatments. Our results indicate that SETDB1 is a major driver of melanoma development and may serve as a potential future target for the treatment of this disease.
What's new?
Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 is known to be involved in malignant melanoma. However, little is known about its effects or mechanisms of action in humans. In this study, the authors found that increased SETDB1 expression is linked to poor prognosis in melanoma patients, and that SETDB1 regulates expression of the oncogene THBS1. They also found that inhibiting SETDB1 leads to a strong reduction in melanoma‐cell viability. This enzyme may thus offer a novel therapeutic target.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>31131878</pmid><doi>10.1002/ijc.32432</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-7413-1383</orcidid><orcidid>https://orcid.org/0000-0001-5316-0241</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 2019-12, Vol.145 (12), p.3462-3477 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2232115728 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
| subjects | Animals Cancer Carcinogenesis - genetics Carcinogenesis - pathology Epigenesis, Genetic - genetics epigenetic regulation gene amplification Gene Expression Regulation, Neoplastic - genetics Histone H3 Histone methyltransferase Histone-Lysine N-Methyltransferase - genetics Histones Histones - genetics Humans Lysine Lysine - genetics Maintenance Medical research Medical treatment Melanoma Melanoma - genetics Melanoma - pathology Mice Mice, Inbred NOD Mice, SCID Phenotypes prognosis SETDB1 Therapeutic applications therapy Thrombospondin tumor progression Tumorigenesis Tumors |
| title | Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T05%3A16%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histone%20methyltransferase%20SETDB1%20contributes%20to%20melanoma%20tumorigenesis%20and%20serves%20as%20a%20new%20potential%20therapeutic%20target&rft.jtitle=International%20journal%20of%20cancer&rft.au=Orouji,%20Elias&rft.date=2019-12-15&rft.volume=145&rft.issue=12&rft.spage=3462&rft.epage=3477&rft.pages=3462-3477&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.32432&rft_dat=%3Cproquest_cross%3E2307156497%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2307156497&rft_id=info:pmid/31131878&rfr_iscdi=true |